Compare Amgen, Inc. (AMGN) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Fiverr International Ltd — how do they compare? Amgen, Inc. trades at $416.09 (market cap $224.14B), while Fiverr International Ltd trades at $8.78 (market cap $314.57M). The key difference: Amgen, Inc. is far larger — about 712.5× Fiverr International Ltd's market cap, and Amgen, Inc. pays a 2.43% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| AMGN | FVRR | |
|---|---|---|
Market Cap | $224.14B | $314.57M |
Sector | Health | Industrials |
52-Week High | $417.20 | $26.67 |
52-Week Low | $271.18 | $8.66 |
Enterprise Value | $267.45B | $66.95M |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Fiverr International (FVRR) trades at $8.66, down 4.73% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation ratios with a P/E of 10.8 and P/S of 0.77, but faces headwinds from AI disruption compressing demand for freelance services. Revenue declined to $97.8 million in Q2 2026 (MarketBeat, July 29, 2026), contributing to a lowered full-year outlook.
The investment outlook is cautious. While valuations appear cheap and the company maintains a strong gross margin of 82%, significant risks from competitive AI technologies and recent execution challenges temper near-term optimism. Analyst consensus leans Hold with a $10.70 price target, suggesting limited upside from current levels amid transitional pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
